Original article—liver, pancreas, and biliary tractClinical and Histopathologic Features of Fluoroquinolone-Induced Liver Injury
Section snippets
Overall Design
The study design of the DILIN prospective study has been described previously.9, 37 Briefly, patients aged 2 or older were enrolled on the basis of clinical suspicion of liver injury caused by a medication or herbal product within 6 months of clinical onset. Inclusion criteria included aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels >5 times the upper limit of normal (or pretreatment baseline if abnormal) on 2 consecutive occasions, or alkaline phosphatase (AP) levels
Subjects
Among 679 cases enrolled in the DILIN database that had undergone causality assessment by February 2010, fluoroquinolones were listed as a potential cause in 30. In 15 cases, fluoroquinolone was the only implicated drug, of which 3 were considered definite, 4 highly likely, 3 probable, and 5 possible or unlikely. Only the 10 single-drug cases that were considered definite, highly likely, or probable were included in this study. Among the other 15 cases in which fluoroquinolones were one of
Discussion
Hepatotoxicity from fluoroquinolones has been described in multiple case reports and summarized in several reviews. However, there are no well-characterized and prospectively followed groups of cases published on hepatic injury from this important class of antibiotics. The 12 cases presented here confirm that hepatic injury from fluoroquinolones has a “class effect,” and the clinical presentation and phenotype of injury are similar with the different agents. The predominant feature of the
Acknowledgments
A full list of DILIN investigators, co-investigators, and staff is shown in Appendix 1 of the supplementary materials. The authors thank our referring providers and patients for participation in this study. We also thank Jay H. Hoofnagle and Robert J. Fontana for their advice and help in preparing this article.
References (54)
- et al.
The safety profile of the fluoroquinolones
Clin Ther
(2000) - et al.
Delayed and prolonged cholestatic hepatitis with ductopenia after long-term ciprofloxacin therapy for Crohn's disease
J Hepatol
(2002) - et al.
Moxifloxacin-induced acute liver injury
Am J Gastroenterol
(2002) - et al.
Acute fatal hepatitis related to levofloxacin
J Hepatol
(2001) - et al.
Cholestatic hepatitis related to quinolones: a report of two cases
J Hepatol
(1995) - et al.
Fatal hepatic failure associated with ciprofloxacin
Lancet
(1994) - et al.
Causality assessment of adverse reactions to drugs: II—an original model for validation of drug causality assessment methods: case reports with positive rechallenge
J Clin Epidemiol
(1993) - et al.
Causality assessment of adverse reactions to drugs: I—a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries
J Clin Epidemiol
(1993) - et al.
Important elements for the diagnosis of drug-induced liver injury
Clin Gastroenterol Hepatol
(2010) - et al.
Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis
Am J Gastroenterol
(2000)
Norfloxacin-induced hepatotoxicity
J Hepatol
Clinical toxicological aspects of fluoroquinolones
Toxicol Lett
Overview of fluoroquinolone safety
Am J Med
Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000
Emerg Infect Dis
Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes
Drug Saf
Latest industry information on the safety profile of levofloxacin in the US
Chemotherapy
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults
Clin Infect Dis
Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women: Infectious Diseases Society of America (IDSA)
Clin Infect Dis
Antimicrobial safety: focus on fluoroquinolones
Clin Infect Dis
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States
Gastroenterology
Drug-induced liver injury
Drug Saf
Drug-related hepatotoxicity
N Engl J Med
Drug-induced liver injury: summary of a single topic clinical research conference
Hepatology
A case report of highly suspected ciprofloxacin-induced hepatotoxicity
Turk J Gastroenterol
Levofloxacin-induced acute fulminant hepatic failure in a patient with chronic hepatitis B infection
Ann Pharmacother
Moxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure
Arch Dermatol
Ciprofloxacin-induced acute liver injury: case report and review of literature
Virchows Arch
Cited by (109)
Hepatic Injury due to Drugs, Dietary and Herbal Supplements, Chemicals and Toxins
2023, MacSween's Pathology of the Liver, Eighth EditionDiscriminative and quantitative color-coding analysis of fluoroquinolones with dual-emitting lanthanide metal-organic frameworks
2022, Sensors and Actuators B: ChemicalDrug-induced liver injury and prospect of cytokine based therapy; A focus on IL-2 based therapies
2021, Life SciencesCitation Excerpt :Other phenotypes of idiosyncratic drug-induced hepatotoxicity include chronic hepatitis, mixed or cholestatic hepatitis, and bland cholestasis. Agents implicated in idiosyncratic hepatotoxicity include amoxicillin-clavulanate, cephalosporins, diclofenac, fluoroquinolones, isoniazid, macrolides antibiotics, and nitrofurantoin [66–69]. The frequency of indirect drug-induced liver injury is intermediate between direct and idiosyncratic hepatotoxicity, where the latency period can be months.
Safety of fluoroquinolones
2024, Revista Espanola de Quimioterapia
Conflicts of interest The authors disclose no conflicts.
Funding The DILIN Network is structured as a U01 cooperative agreement with funds provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under grants: 2U01-DK065176-06 (Duke), 2U01-DK065201-06 (UNC), 2U01-DK065184-06 (Michigan), 2U01-DK065211-06 (Indiana), 5U01DK065193-04 (UConn), 5U01-DK065238-08 (UCSF/CPMC), 1U01-DK083023-01 (UTSW), 1U01-DK083027-01 (TJH/UPenn), 1U01-DK082992-01 (Mayo), 1U01-DK083020-01 (USC). Additional funding is provided by CTSA grants: UL1 RR025761 (Indiana), UL1 RR025747 (UNC), UL1 RR024134 (UPenn), UL1 RR024986 (Michigan), UL1 RR024982 (UTSW), UL1 RR024150 (Mayo) and in part by the Intramural Research Program of the NIH, National Cancer Institute.